VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,481,000 | -40.9% | 102,000 | 0.0% | 0.94% | -38.8% |
| Q3 2016 | $2,504,000 | +21.9% | 102,000 | 0.0% | 1.54% | +24.0% |
| Q2 2016 | $2,054,000 | +41.9% | 102,000 | +85.5% | 1.24% | +37.2% |
| Q1 2016 | $1,447,000 | -80.8% | 55,000 | -25.7% | 0.90% | -79.6% |
| Q4 2015 | $7,522,000 | -15.3% | 74,000 | +48.6% | 4.43% | -19.5% |
| Q3 2015 | $8,880,000 | -28.0% | 49,784 | -10.3% | 5.51% | -18.5% |
| Q2 2015 | $12,326,000 | +11.9% | 55,484 | 0.0% | 6.76% | +10.5% |
| Q1 2015 | $11,020,000 | +38.8% | 55,484 | 0.0% | 6.12% | +29.0% |
| Q4 2014 | $7,940,000 | +9.1% | 55,484 | 0.0% | 4.74% | +3.6% |
| Q3 2014 | $7,280,000 | +22.3% | 55,484 | +17.6% | 4.58% | +15.3% |
| Q2 2014 | $5,953,000 | +100.7% | 47,200 | +109.8% | 3.97% | +62.7% |
| Q1 2014 | $2,966,000 | +12.3% | 22,500 | 0.0% | 2.44% | +22.6% |
| Q4 2013 | $2,641,000 | +12.5% | 22,500 | 0.0% | 1.99% | +7.6% |
| Q3 2013 | $2,347,000 | – | 22,500 | – | 1.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,373,210 | $47,796,000 | 39.06% |
| Claren Road Asset Management, LLC | 77,527 | $1,561,000 | 18.46% |
| Okumus Fund Management Ltd. | 4,242,012 | $85,434,000 | 14.79% |
| Chou Associates Management | 1,446,843 | $29,139,000 | 11.12% |
| FARLEY CAPITAL L.P. | 307,458 | $6,192,000 | 9.65% |
| HAP Trading, LLC | 3,129,700 | $112,397,000 | 6.58% |
| Pershing Square Capital Management | 21,591,122 | $434,845,000 | 5.79% |
| NORTH TIDE CAPITAL, LLC | 2,500,000 | $50,350,000 | 5.61% |
| Convector Capital Management, LP | 192,000 | $3,867,000 | 5.34% |
| Nebula Capital Management, LP | 31,770 | $640,000 | 5.07% |